PRKDC and cancer: In 2022, D’Andreaand co-workers reported an interestingstudy in which they demonstrated that the simultaneous disruptionof the two DNA repair pathways MMEJ, via POLθ inhibitor NVB, and NHEJ, via DNA-PK inhibitor peposertib, led to accumulation of toxic levels of DSB end resection and apoptosis-mediatedcell death, resulting in synergistic SL.121 The synergistic action of the combined treatment was observed acrossmultiple cancer cell lines, including HR-proficient and HR-deficientcells.